RGD Reference Report - Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice.

Authors: Liang, YJ  Chen, SA  Jian, JH 
Citation: Liang YJ, etal., Eur J Pharm Sci. 2011 May 18;43(1-2):65-70. doi: 10.1016/j.ejps.2011.03.011. Epub 2011 Mar 31.
RGD ID: 7244188
Pubmed: PMID:21458563   (View Abstract at PubMed)
DOI: DOI:10.1016/j.ejps.2011.03.011   (Journal Full-text)

Activation of peroxisome proliferator-activated receptor delta (PPARdelta) plays board beneficial effects in treating metabolic syndrome. The aim of this study is to examine whether PPARdelta alters the expression of the receptor for advanced glycation end products (RAGE) and downstream pro-inflammatory cytokines in diabetic nephropathy. Streptozotocin-induced diabetic mice (STZ mice) were injected with a PPARdelta agonist, L-165041 (5 muM/kg, intraperitoneal) once daily for 10 days and high glucose-treated cultured HEK cells were also used. After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice. RAGE mRNA and protein expression were both decreased by L-165041 in kidney tissues of STZ mice. The high glucose incubation increased NF-kappaB, RAGE and IL-6 expressions in HEK293 cells. These effects were inhibited by L-165041 and specific RAGE siRNA transfection. This study demonstrated that PPARdelta may play a beneficial role in preventing diabetic nephropathy. Its downstream signaling may include RAGE and NF-kappaB pathway. Target on PPARdelta will provide new meaningful therapies to patients with diabetic nephropathy.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Experimental Diabetes Mellitus treatmentISOAger (Mus musculus)7244188; 7244188 RGD 
Experimental Diabetes Mellitus treatmentIDA 7244188 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ager  (advanced glycosylation end product-specific receptor)

Genes (Mus musculus)
Ager  (advanced glycosylation end product-specific receptor)

Genes (Homo sapiens)
AGER  (advanced glycosylation end-product specific receptor)


Additional Information